Results 181 to 190 of about 381,362 (315)

Documented End‐of‐Life Preferences of People With Parkinson's Disease or Parkinsonism Across Europe

open access: yesMovement Disorders Clinical Practice, EarlyView.
Abstract Background Parkinson's disease and atypical parkinsonism are characterized by motor and non‐motor symptoms. As the disease advances, planning for end‐of‐life (EoL) care becomes increasingly important. However, consensus‐based European guidelines for advance care planning and documentation of EoL care preferences for parkinsonism are lacking ...
Bauke W. Dijkstra   +30 more
wiley   +1 more source

Non‐Histone Lactylation: A New Frontier in Cerebral Ischemia‐Reperfusion Injury

open access: yesMed Research, EarlyView.
ABSTRACT Reperfusion therapy is the mainstay of treatment for ischemic stroke (IS) but frequently exacerbates secondary injury. Following cerebral ischemia and hypoxia, lactate accumulates markedly. Traditionally regarded as a metabolic byproduct, lactate has gained new significance with the discovery of protein lactylation. In addition to experimental
Minghui Tang   +13 more
wiley   +1 more source

Phase 3b Extension Study MT‐1186‐A04 to Evaluate the Continued Efficacy and Safety of Edaravone Oral Suspension for Up to an Additional 48 Weeks in Patients With Amyotrophic Lateral Sclerosis

open access: yesMuscle &Nerve, EarlyView.
ABSTRACT Introduction/Aims An On/Off dosing regimen of intravenous (IV) edaravone and edaravone oral suspension is currently approved in the US for treatment of amyotrophic lateral sclerosis (ALS). Placebo‐controlled clinical trials showed that IV edaravone slows physical functional decline.
Angela Genge   +17 more
wiley   +1 more source

Home - About - Disclaimer - Privacy